Shenzhen HelpTech Medical Instruments Co., Ltd. Announces Capital Increase in Ruikangtong and Introduction of New Shareholders to Accelerate Neurovascular Interventional Business Expansion

APT Medical (688617.SH) announced that its wholly-owned subsidiary, APT Medical Inc. (“APT Inc.”), is a shareholder of Hunan RECAN Technology Development Co., Ltd. (“RECAN”), holding 30.91% of RECAN’s equity. RECAN plans to increase its registered capital by RMB 1.7895 million, which will be subscribed for by Nantong Huikang Enterprise Management Center (Limited Partnership) (“Nantong Huikang”) and APT Inc. Meanwhile, APT Inc. intends to waive its preemptive right to subscribe for the portion of RECAN’s newly increased registered capital proposed to be contributed by Nantong Huikang.

It is reported that Nantong Huikang and its wholly-owned subsidiary, APT Medical, subscribed to RMB 16.927273 million and RMB 7.572727 million worth of new registered capital in Hunan RECAN Technology Development Co., Ltd., amounting to RMB 1.236388 million and RMB 553,121 respectively. Following the capital increase, Nantong Huikang and APT Medical hold 11.28% and 30.91% equity interests in Hunan RECAN Technology Development Co., Ltd., respectively.

The announcement indicates that the company focuses on the research and development, production, and sales of electrophysiology and vascular interventional medical devices. It has established a business layout dominated by comprehensive coronary access and electrophysiology medical devices, with peripheral vascular and neurointerventional medical devices as key areas for future development. APT Medical’s continued capital increase in Hunan RECAN Technology Development Co., Ltd. is an important manifestation of the company's aforementioned business and product strategies. The products will cover cardiovascular, peripheral vascular, and neurovascular fields, thereby completing the company’s full-line layout in vascular interventional products.

Furthermore, neurointerventional medical devices are characterized by high R&D investment, long development cycles, and significant R&D risks. The newly added partners of Nantong Huikang—Cheng Zhenghui, Xu Yiqing, and Dai Zhenhua—have all worked in the vascular interventional medical device industry for many years, possessing extensive industry experience and resources. Nantong Huikang’s investment in RECAN Technology also helps consolidate additional resources to advance the industrialization of RECAN Technology’s products, thereby accelerating the company’s strategic layout in the neurovascular intervention field.